Sanyuan Biotechnology(SZ:301206) Hua Xia Shi Bao·2025-08-09 10:31Core Viewpoint - The recent announcement by Sanyuan Bio regarding the lifting of restrictions on a significant portion of its shares has raised concerns among investors, particularly in light of the company's operational challenges and reliance on international markets [2][3][5]. Share Unlocking and Market Impact - Sanyuan Bio will unlock 92.946 million shares on August 11, representing 45.94% of its total share capital, primarily held by the controlling shareholder, Nie Zaijian [2][3]. - Out of the unlocked shares, 22.6719 million shares will be available for trading, while 70.2741 million shares will remain locked [3]. - The company has also disclosed that another shareholder, Luxin Capital, plans to reduce its holdings by up to 6 million shares within three months, further intensifying market scrutiny [3]. Market Confidence and Stock Buyback - In response to the potential market pressure from the share unlock and shareholder reductions, Sanyuan Bio has initiated measures to stabilize market confidence, including a share buyback plan with a budget of 50 million to 100 million yuan [4]. - As of July 8, 2025, the company has repurchased approximately 2.33 million shares, accounting for 1.15% of its total share capital, with a total expenditure of about 60.68 million yuan [4]. Operational Challenges - Sanyuan Bio has faced operational challenges, including a significant reliance on international markets, with 70.70% of its revenue coming from exports in 2024 [6]. - The company has experienced revenue fluctuations, with reported revenues of 675 million yuan in 2022, 500 million yuan in 2023, and 713 million yuan in 2024, alongside net profits of 164 million yuan, 56 million yuan, and 105 million yuan for the same years [6]. - The recent imposition of a 450.64% anti-dumping duty by the U.S. Department of Commerce poses additional challenges for the company's sales in the U.S. market [6][7]. Product Structure and Market Dynamics - Sanyuan Bio's product structure is heavily reliant on erythritol, which accounted for 72.30% of its revenue in 2024, raising concerns about vulnerability to market fluctuations [8]. - The erythritol market has experienced significant price volatility, with prices dropping from a peak of 40,000 yuan per ton in 2021 to as low as 9,500 yuan per ton in the first half of 2023 [8]. - The industry is currently in a phase of cyclical volatility, with excess capacity still a concern, although market mechanisms are expected to lead to consolidation and a more favorable competitive landscape for efficient producers [8]. Future Outlook - Sanyuan Bio is at a critical juncture, facing both internal and external pressures, and its ability to navigate these challenges and achieve sustainable growth remains to be seen [9].